— The T cell therapy company heads to ASH 2024 next month to introduce its novel allogeneic protection and cytokine engineering strategies to support the development of potent and persistent off-the-shelf UNi-T cells —
, /PRNewswire/ — Notch Therapeutics, Inc., a biotechnology company developing best-in-class T cell therapies for cancer and autoimmune conditions, is excited to announce the acceptance of two abstracts by the American Society of Hematology (ASH) for poster presentations at the 66th American Society of Hematology Annual Meeting and Exposition in San Diego on December 7-10, 2024. The ASH Annual Meeting and Exposition is one of the largest and most respected global gatherings of clinicians and scientists working to conquer blood diseases.
CAR-T therapies have been transforming the treatment of lymphomas, myelomas, and leukemias for years, but the accessibility and reach of these therapies have been limited.
“Notch continues to focus on developing persistent and potent T cell therapies with patient experience …